Skip to main navigation Skip to search Skip to main content

A Phase 3, Rollover Study to Evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation VX16-809-116

Project: Research

Project Details

StatusFinished
Effective start/end date05/10/17 → 05/10/21

Funding

  • Vertex Pharmaceuticals Incorporated: $53,933.50